|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Tax credit receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets (Note 5) | ||||||||||||||||||||
| Property and equipment held for sale (Note 4) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net (Note 4) | ||||||||||||||||||||
| Operating lease right-of-use assets (Note 15) | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued research and development | ||||||||||||||||||||
| Accrued and other liabilities | ||||||||||||||||||||
| Accrued liabilities (Note 6) | ||||||||||||||||||||
| Operating lease liabilities, current (Note 15) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, non-current (Note 15) | ||||||||||||||||||||
| Long-term debt (Note 7) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, 300,000 shares designated as Series A Junior Participating Preferred Stock at June 30, 2026 and December 31, 2025; and none issued or outstanding at June 30, 2026 and December 31, 2025 (Note 8 and 10) | ||||||||||||||||||||
| Common stock, $0.0001 par value per share; 300,000,000 shares authorized at June 30, 2026 and December 31, 2025; and 61,920,154 and 61,449,290 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively (Note 9) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
